tofacitinib salt (Navipharm)

N/A

Report date: 2026/03/30 17:02:26

Base Information

Drug Nametofacitinib salt (Navipharm)
Drug Alias NametofacitinibNVP-1802
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK3 inhibitorsTyrosine-protein kinase JAK1 inhibitors
TargetsTyrosine-protein kinase JAK3Tyrosine-protein kinase JAK1
Therapy Area/IndicationsArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNavipharm Co
China Registration ClassN/A

Develop Information

Active CompaniesNavipharm Co
Inactive CompaniesN/A
Active IndicationsArthritis, Rheumatoid
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A